|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.Erratum in: CA Cancer J Clin 70: 313. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
International Agency for Research on Cancer (IARC), . World Cancer Report: Cancer Research for Cancer Prevention. Wild CP, Weiderpass E and Stewart BW: IARC; Lyon: 2020
|
|
3
|
Koudelakova V, Kneblova M, Trojanec R, Drabek J and Hajduch M: Non-small cell lung cancer - genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 157:125–136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clausen MM and Langer SW: Improving the prognosis for lung cancer patients. Acta Oncol. 58:1077–1078. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Woodard GA, Jones KD and Jablons DM: Lung cancer staging and prognosis. Cancer Treat Res. 170:47–75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qi Y and Xu R: Roles of PLODs in collagen synthesis and cancer progression. Front Cell Dev Biol. 6:662018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eisinger-Mathason TS, Zhang M, Qiu Q, Skuli N, Nakazawa MS, Karakasheva T, Mucaj V, Shay JE, Stangenberg L, Sadri N, et al: Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 3:1190–1205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang WH, Forde D and Lai AG: Dual prognostic role of 2-oxoglutarate-dependent oxygenases in ten cancer types: Implications for cell cycle regulation and cell adhesion maintenance. Cancer Commun (Lond). 39:232019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li SS, Lian YF, Huang YL, Huang YH and Xiao J: Overexpressing PLOD family genes predict poor prognosis in gastric cancer. J Cancer. 11:121–131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang T, Li Y, Zhu R, Song P, Wei Y, Liang T and Xu G: Transcription factor p53 suppresses tumor growth by prompting pyroptosis in non-small-cell lung cancer. Oxid Med Cell Longev. 2019:87468952019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamada Y, Kato M, Arai T, Sanada H, Uchida A, Misono S, Sakamoto S, Komiya A, Ichikawa T and Seki N: Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: A potential prognostic marker and therapeutic target. Mol Oncol. 13:1898–1912. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu X, Xiang H, Cong W, Yang H, Zhang G, Wang Y, Guo Z, Shen Y and Chen B: PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma. Biochem Biophys Res Commun. 527:29–36. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hollern DP, Honeysett J, Cardiff RD and Andrechek ER: The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol Cell Biol. 34:3229–3243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Denechaud PD, Fajas L and Giralt A: E2F1, a novel regulator of metabolism. Front Endocrinol (Lausanne). 8:3112017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Malaney P, Palumbo E, Semidey-Hurtado J, Hardee J, Stanford K, Kathiriya JJ, Patel D, Tian Z, Allen-Gipson D and Davé V: PTEN physically interacts with and regulates E2F1-mediated transcription in lung cancer. Cell Cycle. 17:947–962. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun CC, Zhou Q, Hu W, Li SJ, Zhang F, Chen ZL, Li G, Bi ZY, Bi YY, Gong FY, et al: Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging (Albany NY). 10:973–987. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao M, Liu Y, Chang J, Qi J, Liu R, Hou Y, Wang Y, Zhang X, Qiao L and Ren L: ILF2 cooperates with E2F1 to maintain mitochondrial homeostasis and promote small cell lung cancer progression. Cancer Biol Med. 16:771–783. 2019.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J, Li W, Zhang J, Ma Z, Wu X and Tang L: Identification of key genes and long non-coding RNA associated ceRNA networks in hepatocellular carcinoma. PeerJ. 7:e80212019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Folk WP, Kumari A, Iwasaki T, Pyndiah S, Johnson JC, Cassimere EK, Abdulovic-Cui AL and Sakamuro D: Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. J Biol Chem. 294:5700–5719. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Du H, Pang M, Hou X, Yuan S and Sun L: PLOD2 in cancer research. Biomed Pharmacother. 90:670–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He J, Wei W, Yang Q and Wang Y: Phillygenin exerts in vitro and in vivo antitumor effects in drug-resistant human esophageal cancer cells by inducing mitochondrial-mediated apoptosis, ROS generation, and inhibition of the nuclear factor kappa B NF-κB signalling pathway. Med Sci Monit. 25:739–745. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang D, Zhang S and Chen F: High expression of PLOD1 drives tumorigenesis and affects clinical outcome in gastrointestinal carcinoma. Genet Test Mol Biomarkers. 22:366–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Allan RJ and Roxon JJ: The effect of dioctyl sodium sulphosuccinate on tartrazine azo reduction by intestinal bacteria. Xenobiotica. 7:181–186. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yin J, Fu W, Dai L, Jiang Z, Liao H, Chen W, Pan L and Zhao J: ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1. Sci Rep. 7:44302017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu B and Liu R: PAQR4 promotes cell proliferation and metastasis through the CDK4-pRB-E2F1 pathway in non-small-cell lung cancer. OncoTargets Ther. 12:3625–3633. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao S, Song Q, Liu J, Zhang X, Ji X and Wang P: E2F1 mediates the downregulation of POLD1 in replicative senescence. Cell Mol Life Sci. 76:2833–2850. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Palomer X, Álvarez-Guardia D, Davidson MM, Chan TO, Feldman AM and Vázquez-Carrera M: The interplay between NF-kappaB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells. PLoS One. 6:e197242011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mia MM and Bank RA: The IκB kinase inhibitor ACHP strongly attenuates TGFβ1-induced myofibroblast formation and collagen synthesis. J Cell Mol Med. 19:2780–2792. 2015. View Article : Google Scholar : PubMed/NCBI
|
